Phathom Pharmaceuticals
PHAT
6.75
-0.07
-0.95%
Phathom Pharmaceuticals
US · PHAT
#3684 by market cap
Listed 2019
6.75
-0.07
-0.95%
Live - 5344 symbols - heartbeat 405s ago
· 2026-10-08 10:00
Pre-market
7.00
+2.79%
After-hours
6.80
-0.15%
- Market cap
- 545.68M
- P/E (TTM)i
- -5.40
- P/Bi
- -1.59
- EPSi
- -3.03
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on PHAT?
Anonymous reader poll. Unscientific, not investment advice.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
- Founded
- 2018
- CEO
- Mr. Steven L. Basta
- Employees
- 371
- Headquarters
- Florham Park, New Jersey, United States of America
- Fiscal year end
- 12-31
- Website
- phathompharma.com
Company profile
- Exchange
- US
- Symbol
- PHAT
- Market-cap rank
- #3684
- Listing date
- 2019-10-25
- Market cap
- 545.68M
- Float cap
- 442.31M
- Shares out
- 80.90M
- Float shares
- 65.58M
Sectors & themes
Quote time 2026-10-08 10:00:25 · For reference only, not investment advice and not tailored to your situation.